Following the second CiteAb Antibody Awards in January this year we will be profiling some of the winners here on our blog.

Today we’re focusing on validation, an issue very close to our heart, and one that is topical following our announcement last week about our involvement in the 2nd International Antibody Validation Meeting.

The winner of our ‘Most exciting antibody validation initiative’ category in this year’s awards was Chicago based company Proteintech.

Proteintech emphasise the development of antibodies from whole proteins, and aims to provide researchers with unmatched reliability and reproducibility. Founded by scientists in 2001 after their continued frustration with failed experiments due to low-grade antibodies, Proteintech states that it is on a path to foster better science by producing the highest quality antibodies for every known human protein.

Proteintech won the ‘Most exciting antibody validation initiative’ award on the back of its tireless work to raise industry standards through its siRNA validation programme.

When judging entries to this CiteAb award, Michael Markie, associate publisher of F1000Research said: “Proteintech have made it their goal to lead the way in raising validation standards through validating their antibody products using RNA interference (RNAi) technology. This addition will nicely complement the wide-ranging validation data of their antibodies and should allow the scientific community to make a more informed decision about the quality of a specific antibody they may want to purchase”.

ValidationInitiative-ProteintechProteintech makes each one of its 12,000+ products in-house from start to finish, and implemented the knockdown method of validation starting in 2014. In December 2015, the company announced plans for the rapid expansion of the program to result in its entire portfolio being verified by this advanced technique over the next several years.

We spoke to Jason Li, Ph.D., CEO of Proteintech, about issues in reproducibility. He explains: “The industry has been plagued by this problem for years because the focus for manufacturers previously was on the quantity of antibodies in a catalogue rather than the quality of the product being produced. Scientific progress continues to be made because good antibodies exist. The problem is we don’t know which ones are good and which ones are bad. The reproducibility crisis can only change when suppliers shoulder greater responsibility for their antibodies.”

And in explanation of Proteintech’s approach, Li added: “The higher standard of testing we’ve introduced is being done to protect researchers in an antibody market laden with problems stemming from reliability. However, while this will make products more reliable, it will not result in price increases for our customers.”

Proteintech also recently announced an extension of its Antibody Exchange Program, which allows a scientist to swap any competitor’s failed antibody for the equivalent from the Proteintech catalogue at no charge. The initiative will now continue in the U.S. until June 30, 2016.

The Antibody Exchange Program is open to both new and existing customers, even those who have previously participated in the exchange. Interested individuals are encouraged to visit for more information.

“Antibodies are such a vital part of research, and antibody companies must meet their obligations to be transparent and offer the best quality products,” said Li. “We are taking these next steps with confidence that our antibodies will work correctly and challenge the rest of industry to meet us in the efforts to improve scientific reproducibility.”

Proteintech will add the technical specifications and validation details, including siRNA results, as the program progresses. For inquiries on the timeline for a specific antibody, researchers can contact the company’s Customer Support directly.

Dr Andrew Chalmers, founder of CiteAb, said: “Here at CiteAb, the quality and reproducibility of antibodies is core to our mission. We congratulate Proteintech on their award win, and look forward to further innovations from a company taking this issue so seriously.

“We’re also very much looking forward to the 2nd International Antibody Validation Meeting, due to be held in Bath next September. Jason Li of Proteintech is among the speakers. You can find out more and sign up to attend here.”

– Matt and the CiteAb team